Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
NCT04926753Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in laryngohypopharyngeal squamous cell carcinoma (LHSCC), sponsored by Ruijin Hospital. Primary endpoint: Objective response rate at 36 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
laryngohypopharyngeal squamous cell carcinoma (LHSCC)
Beyond the preview
Go deeper on NCT04926753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926753.